title: Three-year results of a randomized prospective trial of methionyl human growth hormone and oxandrolone in Turner syndrome.
abstract: Seventy girls with Turner syndrome, 4 to 12 years of age, participated in a prospective, randomized study to determine the effects on growth of methionyl human growth hormone (met-hGH) or oxandrolone. Subjects were randomly assigned to receive either no treatment (control) or met-hGH (0.125 mg/kg three times per week), oxandrolone (0.125 mg/kg/day), or combination met-hGH plus oxandrolone. At the end of an initial period of 12 to 20 months, patients in the original control and oxandrolone groups were given combination met-hGH plus oxandrolone. At that time the dosage of oxandrolone was lowered to 0.0625 mg/kg/day. Sixty-five subjects have now completed the first 3 years of the study. Compared with the control growth rate for year 1 (3.8 cm/yr), significant increases in growth rate were seen in all 3 years of combination therapy (9.8, 7.4, and 6.1 cm/yr, respectively) and in the first 2 years of treatment with met-hGH alone (6.6, 5.4, and 4.6 cm/yr). When growth velocity was expressed as standard deviation for age in girls with Turner syndrome, significant increases relative to the control group for year 1 (-0.1 SD) were seen in all three years of both combination therapy and met-hGH alone (combination, +6.6, +4.3, +3.0 SD; met-hGH, +3.1, +2.0, +1.4 SD). After 3 years of treatment, predicted adult height by the method of Bayley-Pinneau increased 4.5 cm in the met-hGH group and 8.2 cm in the combination group.
authors.affiliation: Department of Pediatrics, Stanford University Medical Center, California.
authors.forename: R G
authors.initials: RG
authors.lastname: Rosenfeld
authors.forename: R L
authors.initials: RL
authors.lastname: Hintz
authors.forename: A J
authors.initials: AJ
authors.lastname: Johanson
authors.forename: B
authors.initials: B
authors.lastname: Sherman
authors.forename: J A
authors.initials: JA
authors.lastname: Brasel
authors.forename: S
authors.initials: S
authors.lastname: Burstein
authors.forename: S
authors.initials: S
authors.lastname: Chernausek
authors.forename: P
authors.initials: P
authors.lastname: Compton
authors.forename: J
authors.initials: J
authors.lastname: Frane
authors.forename: R W
authors.initials: RW
authors.lastname: Gotlin
mesh_terms: D001827:Body Height; D002648:Child; D002675:Child, Preschool; D004359:Drug Therapy, Combination; D005260:Female; D006128:Growth / Q000187:drug effects; D013006:Growth Hormone / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000627:therapeutic use; D006728:Hormones / Q000008:administration & dosage / Q000627:therapeutic use*; D019382:Human Growth Hormone; D006801:Humans; D010074:Oxandrolone / Q000008:administration & dosage / Q000627:therapeutic use*; D011446:Prospective Studies; D011897:Random Allocation; D014424:Turner Syndrome / Q000188:drug therapy*
chemical_list: D006728:Hormones; D019382:Human Growth Hormone; D010074:Oxandrolone; D013006:Growth Hormone